JSPR Jasper Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1788028 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-73.0%
TTM EPS YoY184.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-153.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets14.2%
Debt / equity—
Current ratio10.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.31x
Accruals ratio-106.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| Cost of revenue | $41.63M | $34.27M | — | — | — |
| R&D expense | $63.10M | $55.82M | $51.78M | $34.63M | $25.42M |
| SG&A expense | $20.78M | $20.42M | $17.08M | $16.57M | $11.41M |
| Operating income | -$83.88M | -$76.24M | -$68.86M | -$51.20M | -$36.83M |
| Income tax | — | $2,000 | $2,000 | — | — |
| Net income | -$75.80M | -$71.27M | -$64.47M | -$37.69M | -$30.64M |
| EBITDA | -$82.83M | -$74.87M | -$67.75M | -$50.22M | -$36.46M |
| EPS (basic) | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 |
| EPS (diluted) | -3.95 | -4.89 | -6.18 | -10.33 | -2.69 |
| Weighted avg. shares (diluted) | 19.17M | 14.58M | 10.44M | 3.65M | 11.39M |
| Banking | |||||
| Net interest income | — | — | -$246,000 | -$115,000 | -$80,000 |
| Balance sheet | |||||
| Cash & equivalents | $28.69M | $72.05M | $87.30M | $38.67M | $85.05M |
| Current assets | $34.65M | $75.81M | $88.94M | $41.73M | $87.83M |
| PP&E, net | $102,000 | $1.88M | $2.73M | $3.57M | $3.69M |
| Total assets | $35.78M | $79.90M | $94.89M | $48.36M | $93.65M |
| Current liabilities | $13.20M | $15.24M | $12.37M | $7.07M | $8.02M |
| Total liabilities | $31.63M | $18.23M | $16.45M | $12.37M | $24.14M |
| Shareholders' equity | $4.15M | $61.67M | $78.44M | $35.99M | $69.52M |
| Shares outstanding | 933,242 | 15.02M | 11.16M | 3.80M | 37.86M |
| Cash flow statement | |||||
| Operating cash flow | -$77.16M | -$62.60M | -$52.07M | -$45.86M | -$33.68M |
| Investing cash flow | $5,000 | -$532,000 | -$267,000 | -$576,000 | -$2.43M |
| Financing cash flow | $34.21M | $47.88M | $100.97M | $55,000 | $100.97M |
| Depreciation & amortization | $1.06M | $1.37M | $1.11M | $975,000 | $377,000 |
| Stock-based compensation | $6.71M | $6.62M | $5.21M | $4.09M | $1.05M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.